Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib

Satoshi Shiba, Takuji Okusaka, Masafumi Ikeda, Hidetsugu Saito, Takafumi Ichida

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim: Sorafenib, a multi-targeted tyrosine kinase inhibitor, is a first-line systemic treatment for advanced hepatocellular carcinoma (HCC). However, possible predictors of the efficacy of sorafenib treatment in HCC patients remain unclear. Methods: We conducted a nationwide survey to examine the situation of patients with HCC treated with sorafenib who obtained a complete response (CR) according to the modified response evaluation criteria in solid tumors (mRECIST). The investigation was intended to collect clinical information regarding CR patients and to compare this data with an interim report examining all-patient surveillance for sorafenib use in Japan, which was released in May 2012. Results: Among the 3047 patients who were treated at institutions belonging to the Liver Cancer Study Group of Japan, 18 patients (0.6%) obtained a CR. Significant factors in the CR group were a female sex, a low bodyweight (<59kg), an early clinical stage and a small initial dose of sorafenib (P<0.05). Furthermore, specific adverse events (palmar-plantar erythrodysesthesia syndrome, hypertension, diarrhea, alopecia, fatigue, nausea and anorexia) were frequently observed in the CR group (P<0.05). Conclusion: This study identified the characteristics of CR patients during sorafenib treatment. The evaluation of patients receiving sorafenib, including the investigation of biomarkers, warrants further exploration in future clinical studies to identify a population in which sorafenib treatment is remarkably effective.

Original languageEnglish
Pages (from-to)1268-1276
Number of pages9
JournalHepatology Research
Volume44
Issue number13
DOIs
Publication statusPublished - 2014

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Japan
sorafenib
Alopecia
Anorexia
Liver Neoplasms
Protein-Tyrosine Kinases
Nausea
Fatigue
Diarrhea
Biomarkers
Hypertension
Population

Keywords

  • Adverse drug event
  • Complete response
  • Data collection
  • Hepatocellular carcinoma
  • Population characteristics
  • Sorafenib

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. / Shiba, Satoshi; Okusaka, Takuji; Ikeda, Masafumi; Saito, Hidetsugu; Ichida, Takafumi.

In: Hepatology Research, Vol. 44, No. 13, 2014, p. 1268-1276.

Research output: Contribution to journalArticle

Shiba, Satoshi ; Okusaka, Takuji ; Ikeda, Masafumi ; Saito, Hidetsugu ; Ichida, Takafumi. / Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. In: Hepatology Research. 2014 ; Vol. 44, No. 13. pp. 1268-1276.
@article{646c82a06a3943f7ad510a397f490452,
title = "Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib",
abstract = "Aim: Sorafenib, a multi-targeted tyrosine kinase inhibitor, is a first-line systemic treatment for advanced hepatocellular carcinoma (HCC). However, possible predictors of the efficacy of sorafenib treatment in HCC patients remain unclear. Methods: We conducted a nationwide survey to examine the situation of patients with HCC treated with sorafenib who obtained a complete response (CR) according to the modified response evaluation criteria in solid tumors (mRECIST). The investigation was intended to collect clinical information regarding CR patients and to compare this data with an interim report examining all-patient surveillance for sorafenib use in Japan, which was released in May 2012. Results: Among the 3047 patients who were treated at institutions belonging to the Liver Cancer Study Group of Japan, 18 patients (0.6{\%}) obtained a CR. Significant factors in the CR group were a female sex, a low bodyweight (<59kg), an early clinical stage and a small initial dose of sorafenib (P<0.05). Furthermore, specific adverse events (palmar-plantar erythrodysesthesia syndrome, hypertension, diarrhea, alopecia, fatigue, nausea and anorexia) were frequently observed in the CR group (P<0.05). Conclusion: This study identified the characteristics of CR patients during sorafenib treatment. The evaluation of patients receiving sorafenib, including the investigation of biomarkers, warrants further exploration in future clinical studies to identify a population in which sorafenib treatment is remarkably effective.",
keywords = "Adverse drug event, Complete response, Data collection, Hepatocellular carcinoma, Population characteristics, Sorafenib",
author = "Satoshi Shiba and Takuji Okusaka and Masafumi Ikeda and Hidetsugu Saito and Takafumi Ichida",
year = "2014",
doi = "10.1111/hepr.12297",
language = "English",
volume = "44",
pages = "1268--1276",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "13",

}

TY - JOUR

T1 - Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib

AU - Shiba, Satoshi

AU - Okusaka, Takuji

AU - Ikeda, Masafumi

AU - Saito, Hidetsugu

AU - Ichida, Takafumi

PY - 2014

Y1 - 2014

N2 - Aim: Sorafenib, a multi-targeted tyrosine kinase inhibitor, is a first-line systemic treatment for advanced hepatocellular carcinoma (HCC). However, possible predictors of the efficacy of sorafenib treatment in HCC patients remain unclear. Methods: We conducted a nationwide survey to examine the situation of patients with HCC treated with sorafenib who obtained a complete response (CR) according to the modified response evaluation criteria in solid tumors (mRECIST). The investigation was intended to collect clinical information regarding CR patients and to compare this data with an interim report examining all-patient surveillance for sorafenib use in Japan, which was released in May 2012. Results: Among the 3047 patients who were treated at institutions belonging to the Liver Cancer Study Group of Japan, 18 patients (0.6%) obtained a CR. Significant factors in the CR group were a female sex, a low bodyweight (<59kg), an early clinical stage and a small initial dose of sorafenib (P<0.05). Furthermore, specific adverse events (palmar-plantar erythrodysesthesia syndrome, hypertension, diarrhea, alopecia, fatigue, nausea and anorexia) were frequently observed in the CR group (P<0.05). Conclusion: This study identified the characteristics of CR patients during sorafenib treatment. The evaluation of patients receiving sorafenib, including the investigation of biomarkers, warrants further exploration in future clinical studies to identify a population in which sorafenib treatment is remarkably effective.

AB - Aim: Sorafenib, a multi-targeted tyrosine kinase inhibitor, is a first-line systemic treatment for advanced hepatocellular carcinoma (HCC). However, possible predictors of the efficacy of sorafenib treatment in HCC patients remain unclear. Methods: We conducted a nationwide survey to examine the situation of patients with HCC treated with sorafenib who obtained a complete response (CR) according to the modified response evaluation criteria in solid tumors (mRECIST). The investigation was intended to collect clinical information regarding CR patients and to compare this data with an interim report examining all-patient surveillance for sorafenib use in Japan, which was released in May 2012. Results: Among the 3047 patients who were treated at institutions belonging to the Liver Cancer Study Group of Japan, 18 patients (0.6%) obtained a CR. Significant factors in the CR group were a female sex, a low bodyweight (<59kg), an early clinical stage and a small initial dose of sorafenib (P<0.05). Furthermore, specific adverse events (palmar-plantar erythrodysesthesia syndrome, hypertension, diarrhea, alopecia, fatigue, nausea and anorexia) were frequently observed in the CR group (P<0.05). Conclusion: This study identified the characteristics of CR patients during sorafenib treatment. The evaluation of patients receiving sorafenib, including the investigation of biomarkers, warrants further exploration in future clinical studies to identify a population in which sorafenib treatment is remarkably effective.

KW - Adverse drug event

KW - Complete response

KW - Data collection

KW - Hepatocellular carcinoma

KW - Population characteristics

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84927575845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927575845&partnerID=8YFLogxK

U2 - 10.1111/hepr.12297

DO - 10.1111/hepr.12297

M3 - Article

AN - SCOPUS:84927575845

VL - 44

SP - 1268

EP - 1276

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 13

ER -